Voronoi and Voronoi Bio Inc. have patented serine/threonine-protein kinase B-raf (BRAF), Raf kinase and Raf kinase B (V600E mutant) inhibitors reported to be useful for the treatment of cancer.
A Voronoi Bio Inc. and Voronoi Inc. patent describes platelet-derived growth factor receptor (PDGFR), mast/stem cell growth factor receptor kit (KIT; c-Kit; CD117) and their mutant inhibitors reported to be useful for the treatment of cancer, fibrosis, neurological diseases, atherosclerosis, and pulmonary hypertension.
Researchers at Voronoi Bio Inc. and Voronoi Inc. have disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial infarction, Alzheimer's disease, asthma and type 1 diabetes, among others.
Voronoi Inc. has identified heteroaryl compounds acting as HER2 (erbB2) and/or HER4 (erbB4) inhibitors reported to be useful for the treatment of cancer.
Voronoi Inc. out-licensed its pan-RAF inhibitor program in a deal worth up to $482.2 million with Metis Therapeutics, a company integrating drug discovery and delivery with artificial intelligence and machine learning.
Voronoi Inc. out-licensed its pan-RAF inhibitor program in a deal worth up to $482.2 million with Metis Therapeutics, a company integrating drug discovery and delivery with artificial intelligence and machine learning.
Voronoi Inc. licensed global rights to its monopolar spindle1 (MPS1) inhibitor, VRN-08, and a second undisclosed asset to Pyramid Biosciences Inc. in a deal worth up $846 million that preserves Voronoi’s rights to both assets in South Korea.
